|
1.
|
Jamieson ER and Lippard SJ: Structure,
recognition and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Charalabopoulos K, Karkabounas S, Ioachim
E, et al: Antitumour and toxic effects on Wistar rats of two new
platinum complexes. Eur J Clin Invest. 32:129–133. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Covens A, Carey M, Bryson P, et al:
Systematic review of first-line chemotherapy for newly diagnosed
postoperative patients with stage II, III or IV epithelial ovarian
cancer. Gynecol Oncol. 85:71–80. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Androulakis N, Syrigos K, Polyzos A, et
al: Oxaliplatin for pretreated patients with advanced or metastatic
pancreatic cancer: a multicenter phase II study. Cancer Invest.
23:9–12. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Polyzos A, Syrigos K, Stergiou J, et al:
Phase I trial of weekly docetaxel with a 4-weekly cisplatin
administration in patients with advanced gastric carcinoma. Cancer
Chemother Pharmacol. 55:466–470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Androulakis N, Aravantinos G, Syrigos K,
et al: Oxaliplatin as first-line treatment in inoperable biliary
tract carcinoma: a multi-center phase II study. Oncology.
70:280–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Karapanagiotou EM, Boura PG, Papamichalis
G, et al: Carboplatin-pemetrexed adjuvant chemotherapy in resected
non-small cell lung cancer (NSCLC): a phase II study. Anticancer
Res. 29:4297–4301. 2009.PubMed/NCBI
|
|
8.
|
Syrigos KN, Karachalios D, Karapanagiotou
EM, et al: Head and neck cancer in the elderly: an overview on the
treatment modalities. Cancer Treat Rev. 35:237–245. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Charpidou A, Tsagouli S, Tsimpoukis S, et
al: Triplet combination of carboplatin, irinotecan and etoposide in
the first-line treatment of extensive small-cell lung cancer: a
single-institution phase II study. Anticancer Drugs. 21:651–655.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Bhoola S and Hoskins WJ: Diagnosis and
management of epithelial ovarian cancer. Obstet Gynecol.
107:1399–1410. 2006. View Article : Google Scholar
|
|
11.
|
Trock BJ, Leonessa F and Clarke R:
Multidrug resistance in breast cancer: a meta-analysis of
MDR1/gp170 expression and its possible functional significance. J
Natl Cancer Inst. 89:917–931. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Leith C: Multidrug resistance in leukemia.
Curr Opin Hematol. 5:287–291. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Szakács G, Jakab K, Antal F and Sarkadi B:
Diagnostics of multidrug resistance in cancer. Pathol Oncol Res.
4:251–257. 1998.PubMed/NCBI
|
|
14.
|
Ohsumi Y: Molecular dissection of
autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol.
2:211–216. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Mizushima N: The pleiotropic role of
autophagy: from protein metabolism to bactericide. Cell Death
Differ. 12:1535–1541. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Zhu JH, Horbinski C, Guo F, et al:
Regulation of autophagy by extracellular signal-regulated protein
kinases during 1-methyl-4-phenylpyridiniuminduced cell death. Am J
Pathol. 170:75–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Wang H, Bedford FK, Brandon NJ, Moss SJ
and Olsen RW: GABA(A)-receptor-associated protein links GABA(A)
receptors and the cytoskeleton. Nature. 397:69–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Wang H and Olsen RW: Binding of the
GABA(A) receptor-associated protein (GABARAP) to microtubules and
microfilaments suggests involvement of the cytoskeleton in
GABARAPGABA(A) receptor interaction. J Neurochem. 75:644–655. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kneussel M, Haverkamp S, Fuhrmann JC, et
al: The gamma-aminobutyric acid type A receptor (GABAAR)-associated
protein GABARAP interacts with gephyrin but is not involved in
receptor anchoring at the synapse. Proc Natl Acad Sci USA.
97:8594–8599. 2000. View Article : Google Scholar
|
|
20.
|
Tretter V, Jacob TC, Mukherjee J, et al:
The clustering of GABA(A) receptor subtypes at inhibitory synapses
is facilitated via the direct binding of receptor alpha 2 subunits
to gephyrin. J Neurosci. 28:1356–1365. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Mohrlüder J, Hoffmann Y, Stangler T, Hänel
K and Willbold D: Identification of clathrin heavy chain as a
direct interaction partner for the gamma-aminobutyric acid type A
receptor associated protein. Biochemistry. 46:14537–14543.
2007.PubMed/NCBI
|
|
22.
|
Kanematsu T, Jang I-S, Yamaguchi T, et al:
Role of the PLC-related, catalytically inactive protein p130 in
GABA(A) receptor function. EMBO J. 21:1004–1011. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Green F, O’Hare T, Blackwell A and Enns
CA: Association of human transferrin receptor with GABARAP. FEBS
Lett. 518:101–106. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Okazaki N, Yan J, Yuasa S, et al:
Interaction of the Unc-51-like kinase and microtubule-associated
protein light chain 3 related proteins in the brain: possible role
of vesicular transport in axonal elongation. Brain Res Mol Brain
Res. 85:1–12. 2000. View Article : Google Scholar
|
|
25.
|
Wu M, Yin G, Zhao X, et al: Human RAB24,
interestingly and predominantly distributed in the nuclei of COS-7
cells, is colocalized with cyclophilin A and GABARAP. Int J Mol
Med. 17:749–754. 2006.PubMed/NCBI
|
|
26.
|
Lee JH, Rho SB and Chun T: GABAA
receptor-associated protein (GABARAP) induces apoptosis by
interacting with DEAD (Asp-Glu-Ala-Asp/His) box polypeptide 47
(DDX47). Biotechnol Lett. 27:623–628. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kittler JT, Arancibia-Carcamo IL and Moss
SJ: Association of GRIP1 with a GABA(A) receptor associated protein
suggests a role for GRIP1 at inhibitory synapses. Biochem
Pharmacol. 68:1649–1654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mohrlüder J, Stangler T, Hoffmann Y, et
al: Identification of calreticulin as a ligand of GABARAP by phage
display screening of a peptide library. FEBS J. 274:5543–5555.
2007.PubMed/NCBI
|
|
29.
|
Cook JL, Re RN, deHaro DL, et al: The
trafficking protein GABARAP binds to and enhances plasma membrane
expression and function of the angiotensin II type 1 receptor. Circ
Res. 102:1539–1547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Laínez S, Valente P, Ontoria-Oviedo I, et
al: GABAA receptor associated protein (GABARAP) modulates TRPV1
expression and channel function and desensitization. FASEB J.
24:1958–1970. 2010.PubMed/NCBI
|
|
31.
|
Schwarten M, Mohrlüder J, Ma P, et al: Nix
directly binds to GABARAP: a possible crosstalk between apoptosis
and autophagy. Autophagy. 5:690–698. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Alam J, Deharo D, Redding KM, Re RN and
Cook JL: C-terminal processing of GABARAP is not required for
trafficking of the angiotensin II type 1A receptor. Regul Pept.
159:78–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Klebig C, Seitz S, Arnold W, et al:
Characterization of γ-aminobutyric acid type A receptor-associated
protein, a novel tumor suppressor, showing reduced expression in
breast cancer. Cancer Res. 65:394–400. 2005.
|
|
34.
|
Roberts SS, Mendonça-Torres MC, Jensen K,
Francis GL and Vasko V: GABA receptor expression in benign and
malignant thyroid tumors. Pathol Oncol Res. 15:645–650. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Miao Y, Zhang Y, Chen Y, Chen L and Wang
F: GABARAP is overexpressed in colorectal carcinoma and correlates
with shortened patient survival. Hepatogastroenterology.
57:257–261. 2010.PubMed/NCBI
|
|
36.
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: from innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Oren M: Decision making by p53: life,
death and cancer. Cell Death Differ. 10:431–442. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Steele RJ and Lane DP: P53 in cancer: a
paradigm for modern management of cancer. Surgeon. 3:197–205. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Haldar S, Negrini M, Monne M, Sabbioni S
and Croce CM: Down-regulation of Bcl-2 by p53 in breast cancer
cells. Cancer Res. 54:2095–2097. 1994.PubMed/NCBI
|
|
40.
|
Miyashita T and Reed JC: Tumor suppressor
p53 is a direct transcriptional activator of the human bax gene.
Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Reed JC: Bcl-2 family proteins: regulators
of apoptosis and chemoresistance in hematologic malignancies. Semin
Hematol. 34:9–19. 1997.PubMed/NCBI
|
|
42.
|
Antonsson B and Martinou JC: The Bcl-2
protein family. Exp Cell Res. 256:50–57. 2000. View Article : Google Scholar
|
|
43.
|
Bentires-Alj M, Dejardin E, Viatour P, et
al: Inhibition of the NF-kappaB transcription factor increases Bax
expression in cancer cell lines. Oncogene. 20:2805–2813. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Heckman CA, Mehew JW and Boxer LM:
NF-kappaB activates Bcl-2 expression in t(14:18) lymphoma cells.
Oncogene. 21:3898–3908. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Khwaja A: Akt is more than just a Bad
kinase. Nature. 401:33–34. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
46.
|
McComick F: Cancer: survival pathways meet
their end. Nature. 428:267–269. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Westfall SD: Inhibition of
phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to
carboplatin and allows adjunct chemotherapy treatment. Mol Cancer
Ther. 11:1764–1769. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Shih KK and Chi DS: Maximal cytoreductive
effort in epithelial ovarian cancer surgery. J Gynecol Oncol.
21:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Altaha R, Reed E and Abraham J: Breast and
ovarian cancer genetics and prevention. W V Med J. 99:187–191.
2003.PubMed/NCBI
|
|
50.
|
Wang C, Horiuchi A, Imai T, et al:
Expression of BRCA1 protein in benign, borderline and malignant
epithelial ovarian neoplasms and its relationship to methylation
and allelic loss of the BRCA1 gene. J Pathol. 202:215–223. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Rho SB, Kim BR and Kang S: A gene
signature-based approach identifies thioridazine as an inhibitor of
phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer
cells. Gynecol Oncol. 120:121–127. 2011.PubMed/NCBI
|
|
52.
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Kanematsu T, Mizokami A, Watanabe K and
Hirata M: Regulation of GABAA-receptor surface expression with
special reference to the involvement of GABARAP (GABAA
receptor-associated protein) and PRIP (phospholipase C-related, but
catalytically inactive protein). J Pharmacol Sci. 104:285–292.
2007. View Article : Google Scholar
|
|
54.
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: a link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Malaguarnera L: Implications of apoptosis
regulators in tumorigenesis. Cancer Metastasis Rev. 23:367–387.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Guertin DA and Sabatini DM: An expanding
role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Yuan ZQ, Sun N, Feldman RI, et al:
Frequent activation of AKT2 and induction of apoptosis by
inhibition of phosphoinositide-3-OH kinase/Akt pathway in human
ovarian cancer. Oncogene. 19:2324–2330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Bjornsti MA and Houghton PJ: The mTOR
pathways: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View Article : Google Scholar
|
|
59.
|
Bjornsti MA and Houghton PJ: Lost in
translation: dysregulation of cap-dependent translation and cancer.
Cancer Cell. 5:519–523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Suvasini R and Somasundaram K: Essential
role of PI3K-kinase pathway in p53-mediated transcription:
implications in cancer chemotherapy. Oncogene. 29:3605–3618. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Tonini T, Gabellini C, Bagella L, et al:
pRb2/p130 decreases sensitivity to apoptosis induced by
camptothecin and doxorubicin but not by taxol. Clin Cancer Res.
10:8085–8093. 2004. View Article : Google Scholar : PubMed/NCBI
|
